ZBIO
Zenas BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$32.88
−0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0M | 10.0M | 5.0M | 50.0M | — |
| Cost of Revenue | 60.7M | — | 139.1M | — | 61.7M |
| Gross Profit | (59.7M) | 10.0M | (134.1M) | 50.0M | (61.7M) |
| Operating Expenses | |||||
| R&D Expense | 380.1M | 168.1M | 139.1M | 60.0M | 62.7M |
| SG&A Expense | 61.4M | 53.3M | 29.7M | 17.1M | 13.5M |
| General & Admin Expense | 62.9M | 53.3M | 28.8M | 17.1M | 12.8M |
| Selling & Marketing Expense | (1.5M) | — | 900.0K | — | 700.0K |
| Other Expenses | (25.7M) | — | (139.1M) | 10.0M | (61.7M) |
| Total Operating Expenses | 415.8M | 221.4M | 29.7M | 87.1M | 14.5M |
| Cost and Expenses | 476.6M | 221.4M | 168.9M | 87.1M | 76.2M |
| Operating Income (EBIT) | (475.6M) | (211.4M) | (163.9M) | (37.1M) | (76.2M) |
| Non-Operating | |||||
| Interest Income | 9.6M | 12.2M | — | — | — |
| Interest Expense | 16.9M | 7.3M | — | — | — |
| Net Interest Income | (7.3M) | 4.8M | — | — | — |
| Other Non-Op Income/Expense | (8.6M) | (166.4M) | 7.3M | 324.0K | (43.1M) |
| Non-Operating Income (excl Interest) | (18.3M) | 159.1M | (7.3M) | (10.0M) | (1.0M) |
| EBT (Pre-Tax Income) | (484.2M) | (377.8M) | (156.6M) | (36.8M) | (119.3M) |
| Income Tax Expense | 220.0K | (79.0K) | 429.0K | 301.0K | — |
| Bottom Line | |||||
| Net Income | (484.4M) | (377.7M) | (157.0M) | (37.1M) | (119.3M) |
| Earnings from Cont. Ops | (484.4M) | (377.7M) | (157.0M) | (37.1M) | (119.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (484.4M) | (377.7M) | (157.0M) | (37.1M) | (119.3M) |
| Per Share | |||||
| Basic EPS | ($9.62) | ($8.44) | ($3.76) | ($0.97) | ($3.11) |
| Diluted EPS | ($9.62) | ($8.44) | ($3.76) | ($0.97) | ($3.11) |
| Revenue Per Share | $0.02 | $0.22 | $0.12 | $1.30 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 63.1M | 44.7M | 41.8M | 38.3M | 38.3M |
| Diluted Shares Outstanding | 63.1M | 44.7M | 41.8M | 38.3M | 38.3M |
| Profitability Metrics | |||||
| EBITDA | (457.3M) | (370.4M) | (156.4M) | (27.0M) | (75.1M) |
| D&A | 31.0K | 56.0K | 137.0K | 113.0K | 78.0K |
| EBIT | (457.3M) | (370.5M) | (156.6M) | (27.1M) | (75.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026